Stable dosages of clobazam for <scp>L</scp>ennox‐<scp>G</scp>astaut syndrome are associated with sustained drop‐seizure and total‐seizure improvements over 3 years

Abstract

In this largest and longest-running trial in LGS, adjunctive clobazam sustained seizure freedom and substantial seizure improvements at stable dosages through 3 years of therapy in this difficult- to-treat patient population. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.